Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer

Radiation Oncology

Hiromichi Ishiyama¹  Isao Asakawa²  Iwao Hashida³  Hideyasu Tsumura⁴  Takefumi Satoh⁴  Ken-ichi Tabata⁴  Tomohiko Oguchi⁵  Haruaki Kato⁵  Kazuyoshi Iijima⁵  Nobumichi Tanaka⁶  Yasushi Nakai⁶  Takuya Owari⁶ 

[1] Department of Radiation Oncology, Kitasato University School of Medicine;Department of Radiation Oncology, Nara Medical University;Department of Radiation Therapy, Nagano Municipal Hospital;Department of Urology, Kitasato University School of Medicine;Department of Urology, Nagano Municipal Hospital;Department of Urology, Nara Medical University;

关键词: Brachytherapy;    Intermediate risk;    Prostate cancer;    Radical prostatectomy;   

DOI  :  10.1186/s13014-022-02046-x

来源: DOAJ

【 摘 要 】

Abstract Background We compared the oncological outcomes of patients who received seed brachytherapy (SEED-BT) with those who received radical prostatectomy (RP) for intermediate-risk prostate cancer. Methods Candidates were patients treated with either SEED-BT (n = 933) or RP (n = 334). One-to-one propensity score matching was performed to adjust the patients’ backgrounds. We compared the biochemical recurrence (BCR)-free rate using the Phoenix definition (prostate-specific antigen [PSA] nadir plus 2 ng/mL) for SEED-BT and the surgical definition (PSA cut-off value of 0.2 ng/mL) for RP. We also directly compared the BCR-free rates using the same PSA cut-off value of 0.2 ng/mL for both SEED-BT and RP. Results In the propensity score-matched analysis with 214 pairs, the median follow-up treatment was 96 months (range 1–158 months). Fifty-three patients (24.7%) were treated with combined SEED-BT and external-beam radiotherapy. Forty-three patients (20.0%) received salvage radiotherapy after RP. Comparing the BCR-free rate using the above definitions for SEED-BT and RP showed that SEED-BT yielded a significantly better 8-year BCR-free rate than did RP (87.4% vs. 74.3%, hazard ratio [HR] 0.420, 95% confidence interval [CI] 0.273–0.647). Comparing the 8-year BCR-free rate using the surgical definition for both treatments showed no significant difference between the two treatments (76.7% vs. 74.3%, HR 0.913, 95% CI 0.621–1.341). SEED-BT had a significantly better 8-year salvage hormonal therapy-free rate than did RP (92.0% vs. 85.6%, HR 0.528, 95% CI 0.296–0.942, P = 0.030). The 8-year metastasis-free survival rates (98.5% vs. 99.0%, HR 1.382, 95% CI 0.313–6.083, P = 0.668) and overall survival rates (91.9% vs. 94.6%, HR 1.353, 95% CI 0.690–2.650) did not significantly differ between the treatments. Conclusions The BCR-free rates did not significantly differ between patients treated with SEED-BT and those treated with RP for intermediate-risk prostate cancer even when they were directly compared using the surgical definition for BCR. SEED-BT and RP can be adequately compared for oncological outcomes.

【 授权许可】

Unknown